366 related articles for article (PubMed ID: 36358978)
1. Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration.
ElSheikh RH; Chauhan MZ; Sallam AB
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358978
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy.
Ferrante N; Ritrovato D; Bitonti R; Furneri G
BMC Health Serv Res; 2022 Apr; 22(1):573. PubMed ID: 35484540
[TBL] [Abstract][Full Text] [Related]
3. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
Park DH; Sun HJ; Lee SJ
Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
[TBL] [Abstract][Full Text] [Related]
4. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data.
Korobelnik JF; Delcourt C; Creuzot-Garcher C; Melaine A; Chassetuillier J; Lejeune A; Bénard S; Dupont-Benjamin L
J Med Econ; 2021; 24(1):1087-1097. PubMed ID: 34420480
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic biomolecules in neovascular age-related macular degeneration; therapeutics and drug delivery systems.
Kazemi MS; Shoari A; Salehibakhsh N; Aliabadi HAM; Abolhosseini M; Arab SS; Ahmadieh H; Kanavi MR; Behdani M
Int J Pharm; 2024 Jun; 659():124258. PubMed ID: 38782152
[TBL] [Abstract][Full Text] [Related]
6. Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration.
Khachigian LM; Liew G; Teo KYC; Wong TY; Mitchell P
J Transl Med; 2023 Feb; 21(1):133. PubMed ID: 36810060
[TBL] [Abstract][Full Text] [Related]
7. Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials.
Yamashiro K; Oishi A; Hata M; Takahashi A; Tsujikawa A
Jpn J Ophthalmol; 2021 Nov; 65(6):741-760. PubMed ID: 34491474
[TBL] [Abstract][Full Text] [Related]
8. Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review.
Liberski S; Wichrowska M; Kocięcki J
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012690
[TBL] [Abstract][Full Text] [Related]
9. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
[TBL] [Abstract][Full Text] [Related]
10. Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration.
Hussain RM; Shaukat BA; Ciulla LM; Berrocal AM; Sridhar J
Drug Des Devel Ther; 2021; 15():2653-2665. PubMed ID: 34188445
[TBL] [Abstract][Full Text] [Related]
11. Value of Anti-Vascular Endothelial Growth Factor Gene Therapy for Neovascular Age-Related Macular Degeneration.
Berkowitz ST; Patel S
Ophthalmol Retina; 2021 Apr; 5(4):357-364. PubMed ID: 32818623
[TBL] [Abstract][Full Text] [Related]
12. Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update.
Parravano M; Costanzo E; Scondotto G; Trifirò G; Virgili G
BioDrugs; 2021 Nov; 35(6):673-692. PubMed ID: 34655434
[TBL] [Abstract][Full Text] [Related]
13. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
Brown GC; Brown MM; Rapuano S; Boyer D
Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
[TBL] [Abstract][Full Text] [Related]
14. Anti-VEGF compounds in the treatment of neovascular age related macular degeneration.
Campa C; Harding SP
Curr Drug Targets; 2011 Feb; 12(2):173-81. PubMed ID: 20887245
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on Faricimab in the Treatment of Wet Age-Related Macular Degeneration: Design, Development and Place in Therapy.
Nair AA; Finn AP; Sternberg P
Drug Des Devel Ther; 2022; 16():3395-3400. PubMed ID: 36199631
[TBL] [Abstract][Full Text] [Related]
16. Real-Life Experience with Aflibercept and Ranibizumab in the Treatment of Newly Diagnosed Neovascular Age-Related Macular Degeneration over 24 Months.
Garweg JG; Gerhardt C; Kodjikian L; Pfister IB
J Ocul Pharmacol Ther; 2017 Sep; 33(7):567-572. PubMed ID: 28557667
[TBL] [Abstract][Full Text] [Related]
17. The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration.
Musiał-Kopiejka M; Polanowska K; Dobrowolski D; Krysik K; Wylęgała E; Grabarek BO; Lyssek-Boroń A
Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206485
[TBL] [Abstract][Full Text] [Related]
18. Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration.
Messenger WB; Campbell JP; Faridi A; Shippey L; Bailey ST; Lauer AK; Flaxel CJ; Hwang TS
Br J Ophthalmol; 2014 Sep; 98(9):1205-7. PubMed ID: 24795334
[TBL] [Abstract][Full Text] [Related]
19. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems.
Finger RP; Daien V; Eldem BM; Talks JS; Korobelnik JF; Mitchell P; Sakamoto T; Wong TY; Pantiri K; Carrasco J
BMC Ophthalmol; 2020 Jul; 20(1):294. PubMed ID: 32680477
[TBL] [Abstract][Full Text] [Related]
20. Profiling neovascular age-related macular degeneration choroidal neovascularization lesion response to anti-vascular endothelial growth factor therapy using SSOCTA.
Told R; Reiter GS; Mittermüller TJ; Schranz M; Reumueller A; Schlanitz FG; Weigert G; Pollreisz A; Sacu S; Schmidt-Erfurth U
Acta Ophthalmol; 2021 Mar; 99(2):e240-e246. PubMed ID: 32706171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]